Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Protocol ID
CINC424F12201 / REACH4
Disease (Sub Disease)
Acute Graft Versus Host Disease
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Location
NSW
Sponsor
Novartis Pharmaceuticals
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 17 years
International registry ID's
NCT03491215
Back to Registry
Study Title A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Protocol ID CINC424F12201 / REACH4
Disease (Sub Disease) Acute Graft Versus Host Disease
Diagnosis Stage New Diagnosis
Relapse/Refractory
Location NSW
Sponsor Novartis Pharmaceuticals
Links https://clinicaltrials.gov/ct2/show/NCT03491215
Trial Status Open
Trial Open Date 23/08/2018
Sites Sydney Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility up to 17 years
International registry ID's NCT03491215